Current stock page

Financial Data

NKTR Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

NKTRNektar Therapeutics

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 1/10
$37.27+$0.02 (+0.05%)

Latest quote

  • Momentum
    25
  • Value
    47
  • Quality
    49
  • Risk resilience
    41
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$9.39M$10.13M$10.86M$21.81M$11.79M$11.18M$10.46M$29.18M
Gross Profit-$57.8M$10.13M$10.71M$21.81M$11.59M$11.18M$10.46M$21.2M
Operating Income-$57.8M-$42.34M-$38.26M-$19.09M-$31.53M-$36.23M-$44.54M$14.35M
Net Income-$55.65M-$40.62M-$44.9M-$36.08M-$35.52M-$41.59M-$50.88M$7.26M
EPS-$1.63-$1.23-$1.82-$1.78-$1.87-$2.95-$3.62$0.52
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$71.93M-$75.77M-$44.3M-$64.96M-$48.76M-$45.74M-$49.05M-$46.19M
Capital Expenditure-$398K-$112K-$18K-$18K-$114K-$37K-$2K-$459K
Free Cash Flow-$72.33M-$75.88M-$44.32M-$64.98M-$48.88M-$45.78M-$49.06M-$46.65M
Net Cash Provided By Operating Activities-$71.93M-$75.77M-$44.3M-$64.96M-$48.76M-$45.74M-$49.05M-$46.19M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.04B$1.1B$763.27M$280.41M$301.35M$207.53M$256.24M$303.85M
Total Debt$73.88M$135.93M$143.43M$148.91M$91.92M$96.16M$100.34M$102.56M
Cash And Cash Equivalents$34.69M$39.11M$149.58M$15.12M$41.03M$42.99M$38.89M$44.25M
Total Liabilities$187.53M$192.01M$187.06M$190.57M$216.26M$231.75M$242.5M$243.11M
Total Stockholders Equity$849.72M$903.12M$576.22M$89.83M$85.09M-$24.21M$13.74M$60.74M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio1.52.783.5815.99.13—9.53.15
P/S ratio24.41———————
Debt To Equity0.090.150.251.661.08—7.31.69
Free Cash Flow Yield-20.21%-9.33%-9.89%-14.61%-24.51%-60.73%-136.50%-92.50%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio1.52.783.5815.99.13—9.53.15
P/S ratio24.41———————
Return On Equity-20.86%-17.40%-27.44%-182.65%-141.90%—-9.68%-195.86%
Debt To Equity0.090.150.251.661.08—7.31.69

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-5.77x
Pb1.5x
Revenue Growth Yoy-20.39%
EPS Growth Yoy12.83%
Gross Margin-29.04%
Operating Margin-301.79%
ROE-29.31%
ROIC-15.63%
Debt To Equity0.09
FCF Yield-24.08%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$37.27
Volume695,167
RSI (14)37.87
MACD-2.58
MACD signal-3.43
MACD histogram0.84
ADX (14)32.79
SMA (50)$48.47
SMA (200)$65.05
ATR (14)$2.07
Historical volatility (annualized)48.38%
Volume (20-day average)642,936

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score41/100
Beta1
Annual volatility84.03%
Max Drawdown-64.34%
Sharpe Ratio-0.11
VaR (95%, 1-day)-6.52%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

NKTR Financial Data FAQ

What is Nektar Therapeutics's revenue?

Nektar Therapeutics's revenue is one of the core financial data points for NKTR. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Nektar Therapeutics's revenue growing?

Revenue growth shows whether Nektar Therapeutics is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is NKTR's EPS?

NKTR's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Nektar Therapeutics's net income?

Nektar Therapeutics's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Nektar Therapeutics generate?

Free cash flow shows how much cash Nektar Therapeutics generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Nektar Therapeutics have?

Cash and debt help frame NKTR's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.